CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7004 for the treatment of advanced solid tumors.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. Bob Zhang as President of Metabolic Disease Franchise. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.
Service expected to launch on August 24, covering EU, Swiss, UK and U.S. government and corporate bondsBuilds on successful launch of SFT service in 2025, initially covering European equities and ETFsDemonstrates Cboe's commitment to enhancing its global clearing services
Service expected to launch on August 24, covering EU, Swiss, UK and U.S. government and corporate bondsBuilds on successful launch of SFT service in 2025, initially covering European equities and ETFsDemonstrates Cboe's commitment to enhancing its global clearing services
